Research Domain: Healthcare Systems, Policy, and Disability in ME/CFS

1 Bateman et al. 2021 — ME/CFS: Essentials of Diagnosis and Management

  • Full Citation:: Bateman L, Bested AC, Bonilla HF, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: Essentials of diagnosis and management. Mayo Clinic Proceedings. 2021;96(11):2861–2878. (Bateman et al. 2021)
  • DOI:: 10.1016/j.mayocp.2021.07.004
  • PMID:: 34454716
  • Study Design:: Consensus recommendations from 21 ME/CFS expert clinicians (U.S. ME/CFS Clinical Coalition).
  • Key Findings::
    • Up to 91% of U.S. patients remain undiagnosed; those diagnosed often receive inappropriate treatment
    • Post-COVID-19 illness resembles ME/CFS, increasing clinical urgency
    • IOM 2015 diagnostic criteria adopted by CDC; GET and CBT withdrawn as treatments of choice
    • Provides stepwise clinical guidance: history, physical exam, orthostatic vitals, targeted work-up
    • Pharmacological management by symptom cluster; non-pharmacological: pacing, energy conservation
  • Conclusion:: Generalist and specialist providers can diagnose and manage ME/CFS using existing clinical tools. The undiagnosed majority represents a systems failure, not a knowledge gap per se.
  • Limitations:: Expert consensus, not systematic review; U.S.-centric; no formal guideline development methodology.
  • Diagnostic Criteria:: IOM 2015
  • Certainty:: 0.55 (expert consensus; limited methodological rigor)
  • Population Weight:: 1.00

2 Podell et al. 2020 — Documenting Disability in ME/CFS

  • Full Citation:: Podell R, Dimmock ME, Comerford BB. Documenting disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Work. 2020;66(2):339–352. (Podell, Dimmock, and Comerford 2020)
  • DOI:: 10.3233/WOR-203178
  • PMID:: 32568153
  • Study Design:: Practice guide; review of US disability insurance programs with clinician/attorney co-authors.
  • Key Findings::
    • 1-2.5 million Americans affected; as many as 75% unable to work
    • PEM documentation: 2-day CPET, activity logs, orthostatic intolerance testing provide objective evidence
    • SSDI requires inability to engage in substantial gainful activity for ≥12 months
    • Functional capacity evaluations (FCE) often misleading for ME/CFS due to PEM latency
    • Physical/occupational therapy assessments provide crucial functional evidence
  • Conclusion:: Objective documentation methods exist but are underutilized; clinicians and lawyers lack training on ME/CFS disability claims.
  • Limitations:: Practice guide, not original research; U.S.-specific insurance framework.
  • Diagnostic Criteria:: IOM 2015
  • Certainty:: 0.55 (practice guide; moderate applicability)
  • Population Weight:: 1.00

3 Muirhead et al. 2021 — Medical School Education on ME/CFS

  • Full Citation:: Muirhead N, Muirhead J, Lavery G, Marsh B. Medical school education on Myalgic Encephalomyelitis. Medicina. 2021;57(6):542. (Muirhead et al. 2021)
  • DOI:: 10.3390/medicina57060542
  • PMID:: 34071264
  • PMCID:: PMC8230290
  • Study Design:: Cross-sectional survey of all 34 UK medical schools (22 responses; 65%).
  • Key Findings::
    • 59% (13/22) taught ME/CFS; teaching led by lecturers from 10 different medical specialties
    • Delivery usually by lecture; discussion, case studies, e-learning also used
    • Only 7 schools included ME/CFS questions in examinations
    • Only 3 schools reported likely clinical exposure to ME/CFS patients
    • Two-thirds of respondents interested in receiving further teaching aids
    • No school shared their teaching syllabus – teaching content remains unknown
  • Conclusion:: Inadequacies in UK medical school education on ME/CFS. GMC and MSC urged to reform curricula and consider creating a registered specialty encompassing ME/CFS, post-viral fatigue and Long COVID.
  • Limitations:: 35% non-response rate; self-report without syllabus verification; UK only; academic year 2018-2019.
  • Diagnostic Criteria:: Not specified (survey)
  • Certainty:: 0.60 (moderate response rate; single country; no content verification)
  • Population Weight:: 1.00

4 Bontempo et al. 2025 — Consequences of Invalidation in Health Care

  • Full Citation:: Bontempo AC, Bontempo JM, Duberstein PR. Ignored, dismissed, and minimized: Understanding the harmful consequences of invalidation in health care—A systematic meta-synthesis of qualitative research. Psychological Bulletin. 2025;151(4):399–427. (Bontempo, Bontempo, and Duberstein 2025)
  • DOI:: 10.1037/bul0000473
  • PMID:: 40310228
  • Study Design:: Systematic meta-synthesis of qualitative research; 151 reports, 11,307 individuals across 11 contested illnesses.
  • Key Findings::
    • Four consequence classes of invalidation: induced emotional states (shame, suicidality), healthcare-related anxiety/trauma, healthcare system avoidance, diagnostic delay
    • ME/CFS was one of 11 contested illnesses showing consistent invalidation patterns
    • Novel conceptual model: invalidation → negative emotional states → healthcare avoidance → worsening outcomes → further invalidation (vicious cycle)
    • Symptom invalidation common across diverse conditions sharing ambiguous etiology and female predominance
  • Conclusion:: Healthcare provider invalidation causes measurable psychological and behavioral harm. Policies and interventions must address this at the system level.
  • Limitations:: Qualitative synthesis – no quantitative effect sizes; predominantly Western samples; publication bias likely.
  • Diagnostic Criteria:: Not applicable (meta-synthesis)
  • Certainty:: 0.75 (rigorous meta-synthesis; large sample; high-impact journal)
  • Population Weight:: 0.85 (ME/CFS among 11 contested illnesses; effects validated across conditions)

5 Smith et al. 2014 — AHRQ Diagnosis and Treatment of ME/CFS

6 Kingdon et al. 2022 — NICE Guideline for ME/CFS: What Primary Care Needs to Know

  • Full Citation:: Kingdon C, Lowe A, Shepherd C, Nacul L. What primary care practitioners need to know about the new NICE guideline for myalgic encephalomyelitis/chronic fatigue syndrome in adults. Healthcare. 2022;10(12):2438. (Kingdon et al. 2018)
  • DOI:: 10.3390/healthcare10122438
  • PMID:: 36553962
  • PMCID:: PMC9778354
  • Study Design:: Narrative summary/commentary on NICE NG206 (2021) for primary care practitioners.
  • Key Findings::
    • NICE NG206 (October 2021): diagnosis possible after 3 months (reduced from 6)
    • PEM recognized as core diagnostic symptom
    • GET must not be offered; CBT only as supportive intervention
    • Individual, tailored management by multi-disciplinary team
    • Included people with lived experience as full committee members
    • Rigorous GRADE methodology with patient testimony integration
  • Conclusion:: NICE 2021 represents a paradigm shift in ME/CFS clinical guidance. Primary care education on new guideline is critical for implementation.
  • Limitations:: Commentary/summary, not original research; UK-specific guideline.
  • Diagnostic Criteria:: NICE NG206 (2021)
  • Certainty:: 0.50 (commentary, not primary evidence; guideline summary)
  • Population Weight:: 1.00

7 Smith et al. 2014 — AHRQ Diagnosis and Treatment of ME/CFS

  • Full Citation:: Smith MEB, Nelson HD, Haney E, et al. Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Evidence Report/Technology Assessment. 2014;(219):1–433. (Smith et al. 2014)
  • DOI:: 10.23970/AHRQEPCERTA219
  • PMID:: 30313001
  • Study Design:: AHRQ systematic review; 6175 articles identified, 71 studies included (36 diagnostic, 35 treatment).
  • Key Findings::
    • Eight case definitions compared; Oxford least restrictive; no reference standard exists
    • Rintatolimod improved exercise performance (low strength of evidence)
    • CBT and GET improved fatigue, function, and quality of life (low to moderate SOE)
    • GET associated with higher numbers of adverse events vs CBT or controls
    • No diagnostic method adequately validated in populations with diagnostic uncertainty
    • Perceived stigma, misdiagnosis burden, legitimacy feelings upon diagnosis documented
  • Conclusion:: No diagnostic methods adequately validated; treatment evidence limited with methodological shortcomings. Research gaps are extensive and fundamental.
  • Limitations:: Search through Sep 2014 (predates IOM 2015, NICE 2021); Oxford criteria inclusion weakens specificity; limited to RCTs and controlled studies.
  • Diagnostic Criteria:: Multiple (all major criteria sets through 2014)
  • Certainty:: 0.70 (AHRQ systematic review; high methodological rigor; now dated)
  • Population Weight:: 1.00

8 Parslow et al. 2017a — Children’s Experiences of CFS/ME (Meta-Ethnography)

  • Full Citation:: Parslow RM, Harris S, Broughton J, Alattas A, Crawley E, Haywood K, Shaw A. Children’s experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review and meta-ethnography of qualitative studies. BMJ Open. 2017;7(1):e012633. (Parslow et al. 2017)
  • DOI:: 10.1136/bmjopen-2016-012633
  • PMID:: 28087544
  • PMCID:: PMC5253584
  • Study Design:: Systematic review and meta-ethnography; 10 studies, 82 children aged 8–18.
  • Key Findings::
    • Four third-order constructs: disruption/loss (physical, social, self), barriers to coping (uncertainty, diagnosis problems, disbelief), facilitators (credible illness narratives, supportive relationships), hope/growth/recovery
    • Biographical disruption profound: affects socializing, school performance, future outlook
    • Unfamiliarity of condition, diagnostic problems, and felt stigma impede new illness identity formation
    • Children adopt coping strategies including building credible explanations for their illness
  • Conclusion:: Physical, social, emotional, and self-dimensions must be included in treatment and outcome measurement. Need for greater recognition, specialist activity management, and health-education communication.
  • Limitations:: Small number of included studies (10); predominantly UK samples; heterogeneity in study designs.
  • Diagnostic Criteria:: NICE 2007 (studies predate NICE 2021)
  • Certainty:: 0.65 (rigorous qualitative synthesis; limited study pool)
  • Population Weight:: 1.00

9 Parslow et al. 2017b — Health Professional Perspectives on Pediatric CFS/ME

  • Full Citation:: Parslow RM, Shaw A, Haywood KL, Crawley E. Important factors to consider when treating children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): Perspectives of health professionals from specialist services. BMC Pediatrics. 2017;17(1):43. (Parslow et al. 2017)
  • DOI:: 10.1186/s12887-017-0799-7
  • PMID:: 28143516
  • PMCID:: PMC5286567
  • Study Design:: Qualitative focus groups and interviews; 15 health professionals from 4 largest NHS England specialist pediatric CFS/ME services.
  • Key Findings::
    • Four clinical assessment domains: symptoms, physical function, participation (school, activities, social life), emotional wellbeing
    • Contextual factors critical: illness complexity, family dynamics, educational engagement
    • Physical function improvement desirable but must be balanced against school/social participation
    • Health professionals identified need for child-specific Patient Reported Outcome Measures (PROMs)
  • Conclusion:: Clinically important outcomes span multiple health domains. Results will inform development of child-specific PROM with clinical utility.
  • Limitations:: Small sample (15 HCPs); England only; perspectives from specialist services only (not community/primary care).
  • Diagnostic Criteria:: NICE 2007
  • Certainty:: 0.60 (qualitative; small sample; specialist services only)
  • Population Weight:: 1.00

10 Thornton et al. 2025 — Managing Energy and Shaping Care Through Co-Production

  • Full Citation:: Thornton EJ, Hayes LD, Goodwin DS, Sculthorpe N, Prior Y, Sanal-Hayes NEM. Managing energy, and shaping care: Insights from adults with myalgic encephalomyelitis/chronic fatigue syndrome through co-production workshops. American Journal of Medicine. 2025;138(6):1001–1009. (Thornton et al. 2025)
  • DOI:: 10.1016/j.amjmed.2025.02.008
  • PMID:: 39961545
  • Study Design:: Co-production workshops; 8 adults with ME/CFS + 3 health practitioners; thematic analysis.
  • Key Findings::
    • Early support after diagnosis critical; current delays compound harm
    • Healthcare provider training and public education needed to combat stigma
    • Patient collaboration and research-informed practices valued
    • Multidisciplinary teams and mHealth integration desired
    • Comprehensive approach recommended: sleep, diet, psychological support alongside activity pacing
    • Activity pacing interventions lack rigor and technological integration
  • Conclusion:: Patient co-production reveals actionable priorities for ME/CFS care redesign. Current pacing interventions need modernization via mHealth and multidisciplinary integration.
  • Limitations:: Very small sample (n=8 patients); self-selected participants; UK-based; health practitioners contributed via email only.
  • Diagnostic Criteria:: Not specified
  • Certainty:: 0.50 (small qualitative study; preliminary)
  • Population Weight:: 1.00

11 Swedo et al. 1998 — First 50 Cases of PANDAS

  • Full Citation:: Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. The American Journal of Psychiatry. 1998;155(2):264–271. (Swedo et al. 1998)
  • DOI:: 10.1176/ajp.155.2.264
  • PMID:: 9464208
  • Study Design:: Retrospective case series (n=50)
  • Key Findings::
    • Children with abrupt-onset OCD/tic disorders temporally related to GAS infection
    • 80% had symptom onset before age 9
    • Symptom exacerbations correlated with GAS infection episodes in 31/50 (62%)
    • Defined diagnostic criteria for PANDAS
  • Relevance:: Foundational paper establishing PANDAS as a clinical entity. The abrupt onset and infection trigger pattern mirrors post-infectious ME/CFS onset. Architecture B prototype: infection → neuropsychiatric phenotype.
  • Limitations:: Post-hoc retrospective case review; no control group; GAS testing not uniform.
  • Certainty:: 0.60

12 Kirvan et al. 2003 — Molecular Mimicry in Sydenham Chorea

  • Full Citation:: Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nature Medicine. 2003;9(7):914–920. (Kirvan et al. 2003)
  • DOI:: 10.1038/nm892
  • PMID:: 12819778
  • Study Design:: In vitro mechanistic study using human monoclonal antibodies
  • Key Findings::
    • Monoclonal chorea antibodies cross-react with GAS N-acetyl-beta-D-glucosamine and neuronal lysoganglioside
    • Antibodies activate CaM kinase II (CaMKII) in neuronal cells — the first demonstration of antibody-mediated neuronal cell signaling
    • Tyrosine hydroxylase elevated in dopaminergic neurons upon antibody binding
    • Defines the molecular mimicry pathway: GAS → anti-neuronal antibodies → CaMKII activation → neuropsychiatric phenotype
  • Relevance:: Core mechanism for Architecture B. Establishes that antibodies can alter neuronal signaling through a specific kinase pathway. CaMKII relevant to cardiac, muscle, and neuronal dysfunction in ME/CFS.
  • Limitations:: In vitro; monoclonal antibodies may not represent polyclonal patient response; Sydenham chorea model (PANDAS inferred).
  • Certainty:: 0.80

13 Kirvan et al. 2006 — CaMKII Signaling in PANDAS

  • Full Citation:: Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham’s chorea. Autoimmunity. 2006;39(1):21–29. (Kirvan et al. 2006)
  • DOI:: 10.1080/08916930500484757
  • PMID:: 16455579
  • Study Design:: Mechanistic study (in vitro + patient sera)
  • Key Findings::
    • GAS-induced antibodies cross-react with neuronal cell surface antigens
    • Antibodies signal CaMKII elevation and tyrosine hydroxylase upregulation in dopaminergic neurons
    • Provides mechanism linking streptococcal infection to dopaminergic dysregulation in basal ganglia
    • Replicates and extends the 2003 findings with additional patient samples
  • Relevance:: Replicated mechanism. CaMKII pathway directly relevant to ME/CFS calcium signaling, muscle dysfunction, and neuroinflammation hypotheses.
  • Limitations:: In vitro; relies on serum samples from clinical cohorts; no in vivo validation.
  • Certainty:: 0.70

14 Chang et al. 2015 — PANS Consensus Conference

  • Full Citation:: Chang K, Frankovich J, Cooperstock M, et al. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):3–13. (Chang et al. 2015)
  • DOI:: 10.1089/cap.2014.0084
  • PMID:: 25325534
  • Study Design:: Expert consensus guidelines
  • Key Findings::
    • PANS diagnostic criteria: abrupt-onset OCD/restricted eating + >=2 neuropsychiatric symptoms
    • Broader than PANDAS — covers all triggers (viral, post-infectious, inflammatory), not just GAS
    • Infectious trigger not required for diagnosis
    • Recommends tiered evaluation: psychiatric assessment → infectious workup → immunological testing
  • Relevance:: Consensus operationalization of the neuroimmune encephalopathy spectrum — PANS covers what PANDAS leaves out. The broad trigger criterion mirrors ME/CFS heterogeneity.
  • Limitations:: Consensus-based; may over-capture; limited validation data at time of publication.
  • Certainty:: 0.70

15 Murphy et al. 2014 — PANS Review

  • Full Citation:: Murphy TK, Gerardi DM, Leckman JF. Pediatric acute-onset neuropsychiatric syndrome. The Psychiatric Clinics of North America. 2014;37(3):353–374. (Murphy, Gerardi, and Leckman 2014)
  • DOI:: 10.1016/j.psc.2014.06.001
  • PMID:: 25150567
  • Study Design:: Narrative review
  • Key Findings::
    • Evolution of nosology: PITANDS → PANDAS → PANS
    • Proposed pathophysiology: autoimmune, inflammatory, and infectious mechanisms
    • Includes discussion of treatment with antibiotics and immunomodulation
    • Notes that anti-neuronal antibodies found in some but not all PANS/PANDAS patients
  • Relevance:: Comprehensive overview of the field’s conceptual evolution. The PITANDS→PANDAS→PANS trajectory mirrors how ME/CFS diagnostic concepts have expanded over time.
  • Limitations:: Narrative review; reflects author perspective; rapidly superseded by newer data.
  • Certainty:: 0.65

16 Frankovich et al. 2015 — Stanford PANS Clinic Cohort

  • Full Citation:: Frankovich J, Thienemann M, Pearlstein J, Crable A, Brown K, Chang K. Multidisciplinary clinic dedicated to treating youth with pediatric acute-onset neuropsychiatric syndrome: presenting characteristics of the first 47 consecutive patients. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):38–47. (Frankovich et al. 2015)
  • DOI:: 10.1089/cap.2014.0081
  • PMID:: 25695943
  • Study Design:: Retrospective case series (n=47)
  • Key Findings::
    • Mean age 12.2 ± 4.3 years
    • 68% sudden onset (\(<\) 48 hours); 87% had OCD; 83% had behavioral regression
    • Co-occurring conditions: 62% anxiety, 49% mood disorder
    • Demonstrates a recognizable clinical syndrome distinct from primary OCD
  • Relevance:: Clinical data establishing PANS as a recognizable phenotype. The behavioral regression and acute onset pattern that leads parents to seek PANS evaluation rather than (or after) an autism diagnosis.
  • Limitations:: Single center; referral bias; no control group; small sample.
  • Certainty:: 0.60

17 Frankovich et al. 2017 — Immunomodulatory Therapies for PANS

  • Full Citation:: Frankovich J, Swedo S, Murphy T, et al. Clinical management of pediatric acute-onset neuropsychiatric syndrome: part II — use of immunomodulatory therapies. Journal of Child and Adolescent Psychopharmacology. 2017;27(7):574–593. (Frankovich et al. 2017)
  • DOI:: 10.1089/cap.2016.0148
  • PMID:: 36358107
  • Study Design:: Expert consensus; treatment protocol
  • Key Findings::
    • Tiered immunomodulation: NSAIDs → corticosteroids → IVIG/TPA → rituximab/MMF
    • IVIG dosing: 1.5–2.0 g/kg
    • TPA: 5–7 procedures over 10–14 days
    • Contraindications, monitoring protocols, and escalation criteria specified
  • Relevance:: The treatment pyramid for immune-mediated neuropsychiatric disease. Analogous to emerging immunomodulation approaches in ME/CFS (immunoadsorption trials, IVIG case series).
  • Limitations:: Consensus-based, not evidence-based; RCT evidence for most tiers lacking.
  • Certainty:: 0.65

18 Latimer et al. 2015 — Therapeutic Plasma Apheresis in PANDAS

  • Full Citation:: Latimer ME, L’Etoile N, Seidlitz J, Swedo SE. Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):70–75. (Latimer et al. 2015)
  • DOI:: 10.1089/cap.2014.0080
  • PMID:: 25658452
  • Study Design:: Open-label case series (n=35)
  • Key Findings::
    • Therapeutic plasma apheresis: 5–6 procedures over 10–14 days
    • 89% responders (CGI-I ≤2) at 6 months; 100% at 12 months
    • Responders included those who had failed IVIG
    • Adverse events: transient hypotension, hypocalcemia (manageable)
  • Relevance:: Strongest treatment response signal in PANDAS literature. Response rates parallel apheresis/immunoadsorption response rates seen in ME/CFS subgroups.
  • Limitations:: Open-label, no control group, no blinding, single center, selection bias.
  • Certainty:: 0.55

19 Kovacevic et al. 2015 — IVIG in PANDAS Case Series

  • Full Citation:: Kovacevic M, Grant P, Swedo SE. Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):65–69. (Kovacevic, Grant, and Swedo 2015)
  • DOI:: 10.1089/cap.2014.0067
  • PMID:: 25658609
  • Study Design:: Retrospective case series (n=12)
  • Key Findings::
    • IVIG 1.5–2.0 g/kg
    • 83% showed improvement within 4–6 weeks
    • Improvements sustained from 6 months to 4.5 years follow-up
    • First description of long-term IVIG outcomes in PANDAS
  • Relevance:: Small but positive signal. Early improvement with sustained benefit mirrors the pattern seen in ME/CFS IVIG responders.
  • Limitations:: Very small (n=12); retrospective; no control; single center.
  • Certainty:: 0.50

20 Williams et al. 2016 — IVIG RCT in PANDAS

  • Full Citation:: Williams KA, Swedo SE, Farmer CA, et al. Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Journal of the American Academy of Child and Adolescent Psychiatry. 2016;55(10):860–867.e2. (Williams et al. 2016)
  • DOI:: 10.1016/j.jaac.2016.06.017
  • PMID:: 27663941
  • Study Design:: Double-blind RCT (n=35)
  • Key Findings::
    • IVIG 1.5 g/kg vs placebo
    • Primary outcome (CY-BOCS at 6 weeks): IVIG not significantly superior to placebo — both groups improved
    • Post-hoc: GAS culture-positive patients showed greater IVIG response
    • Overall modest evidence — underpowered
  • Relevance:: The only RCT in PANDAS. The failure to show superiority despite positive case series mirrors ME/CFS immunotherapy trials — heterogeneity requires biomarker-guided selection.
  • Limitations:: Underpowered (n=35); short follow-up (6 weeks); post-hoc subgroup analysis.
  • Certainty:: 0.70

21 Sigra et al. 2018 — Treatment of PANDAS/PANS Systematic Review

  • Full Citation:: Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: a systematic review. Neuroscience & Biobehavioral Reviews. 2018;86:51–65. (Sigra, Hesselmark, and Bejerot 2018)
  • DOI:: 10.1016/j.neubiorev.2018.01.001
  • PMID:: 29309797
  • Study Design:: Systematic review (23 studies)
  • Key Findings::
    • 4 RCTs, 19 case series/cohorts
    • IVIG: sig. improvement in OCD/tic symptoms in case series; RCT evidence weak
    • Antibiotics: prophylactic penicillin failed in RCT
    • Tonsillectomy: limited and inconsistent evidence
    • Plasma exchange: positive case series but no RCT
    • Overall quality of evidence: low
  • Relevance:: Gold standard summary of PANDAS/PANS treatment evidence. The pattern — positive case series, negative or weak RCTs — mirrors early ME/CFS immunotherapy literature and highlights the stratification imperative.
  • Limitations:: Covers only studies through ~2017; most included studies had high risk of bias.
  • Certainty:: 0.80

22 Chiarello et al. 2017 — PANDAS/PANS Controversies

  • Full Citation:: Chiarello F, Spitoni S, Hollander E, Matucci Cerinic M, Pallanti S. An expert opinion on PANDAS/PANS: highlights and controversies. International Journal of Psychiatry in Clinical Practice. 2017;21(2):91–98. (Chiarello et al. 2017)
  • DOI:: 10.1080/13651501.2017.1285941
  • PMID:: 28498087
  • Study Design:: Expert review
  • Key Findings::
    • After 20+ years, PANDAS not accepted as distinct disorder by most clinical bodies
    • Main debates: (1) diagnostic criteria reliability, (2) GAS alone vs any infection, (3) biomarker inconsistency, (4) weak treatment evidence
    • Mirrors broader controversies about autoimmune neuropsychiatric disorders
  • Relevance:: The PANDAS controversy structurally identical to ME/CFS biological-vs-psychosomatic debate. Syndromic labels obscure mechanism-based subgroups in both conditions.
  • Limitations:: Expert opinion, limited systematic methodology.
  • Certainty:: 0.65

23 La Bella et al. 2023 — PANDAS: Myth or Reality?

  • Full Citation:: La Bella S, Scorrano G, Rinaldi M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): myth or reality? The state of the art on a controversial disease. Microorganisms. 2023;11(10):2549. (La Bella et al. 2023)
  • DOI:: 10.3390/microorganisms11102549
  • PMID:: 37894207
  • Study Design:: Comprehensive narrative review
  • Key Findings::
    • Molecular mimicry evidence: GAS antigens cross-reactive with basal ganglia proteins
    • CaMKII pathway in PANDAS: well-established in Sydenham chorea, suggestive in PANDAS
    • Dopamine receptor autoantibodies found in some patients
    • Cunningham Panel sensitivity/specificity data limited — utility debated
    • Conclusion: biologically plausible but evidence still incomplete
  • Relevance:: Most balanced and current review. Useful for understanding which molecular pathways are established vs speculative in PANDAS.
  • Limitations:: Narrative review; no meta-analytic component.
  • Certainty:: 0.70

24 Vreeland et al. 2023 — Postinfectious OCD Spectrum

  • Full Citation:: Vreeland A, Calaprice D, Or-Geva N, et al. Postinfectious inflammation, autoimmunity, and obsessive-compulsive disorder: Sydenham chorea, pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection, and pediatric acute-onset neuropsychiatric disorder. Developmental Neuroscience. 2023;45(6):361–374. (Vreeland et al. 2023)
  • DOI:: 10.1159/000534261
  • PMID:: 37742615
  • Study Design:: Narrative review
  • Key Findings::
    • Links Sydenham chorea → PANDAS → PANS as a spectrum of post-infectious autoimmune OCD
    • Diverse infections (GAS, viruses, Lyme) trigger anti-basal ganglia autoantibodies
    • Dopamine receptor autoantibodies particularly implicated in symptom generation
    • Evidence supports immunomodulatory treatment in some patients
  • Relevance:: The “spectrum” framing directly parallels the neuroimmune encephalopathy spectrum concept in the paper: PANS, post-infectious ME/CFS, Long COVID, and regressive autism subset may share underlying autoimmune pathology.
  • Limitations:: Narrative review; no original data; assumes pathophysiological continuity.
  • Certainty:: 0.65

25 Endres et al. 2022 — Autoimmune OCD Subtype

  • Full Citation:: Endres D, Pollak TA, Bechter K, et al. Immunological causes of obsessive-compulsive disorder: is it time for the concept of an “autoimmune OCD” subtype? Translational Psychiatry. 2022;12(1):5. (Endres et al. 2022)
  • DOI:: 10.1038/s41398-021-01700-4
  • PMID:: 35013105
  • Study Design:: Narrative review synthesizing PANDAS/PANS with broader autoimmune OCD literature
  • Key Findings::
    • Proposes an “autoimmune OCD” subtype with red flags: acute onset, infection trigger, neurological soft signs, anti-neuronal antibodies, immunotherapy response
    • PANDAS/PANS as the pediatric prototype
    • Autoimmune OCD may extend beyond streptococcus to other triggers
    • Recommends CSF analysis (Oligoclonal bands, anti-neuronal Abs) in suspicious cases
  • Relevance:: The “autoimmune OCD” concept is structurally identical to the paper’s argument that an autoimmune ME/CFS subgroup exists. Mechanism-based stratification over syndromic labeling.
  • Limitations:: Narrative review; speculative subtype framework; limited treatment evidence.
  • Certainty:: 0.70

26 Cesaroni et al. 2026 — PANDAS Diagnostic Conundrum

  • Full Citation:: Cesaroni CA, Pisanò G, Rizzi S, Pantani A, Frattini D, Fusco C. PANDAS syndrome: a narrative review of the diagnostic conundrum in children with acute neuropsychiatric symptoms. International Journal of Molecular Sciences. 2026;27(10):4612. (Cesaroni et al. 2026)
  • DOI:: 10.3390/ijms27104612
  • PMID:: 42196589
  • Study Design:: 2026 narrative review
  • Key Findings::
    • Hypothesis: GAS triggers autoimmune cascade targeting basal ganglia dopaminergic circuits → OCD/tic/chorea depending on receptor subtype
    • Molecular evidence exists for this hypothesis but independent replication lacking
    • Cunningham Panel utility still debated — low specificity concerns
    • Calls for large-scale studies with standardized autoantibody testing
  • Relevance:: Most recent (2026) comprehensive review. Confirms that the molecular evidence exists but is not yet replicable at scale — a pattern familiar in ME/CFS biomarker research.
  • Limitations:: Narrative; no new data; relies on same evidence base as earlier reviews.
  • Certainty:: 0.65

27 Masterson et al. 2025 — PANS Clinical Classification

  • Full Citation:: Masterson EE, Miles K, Schlenk N, et al. Defining clinical course of patients evaluated for pediatric acute-onset neuropsychiatric syndrome: phenotypic classification based on 10 years of clinical data. Developmental Neuroscience. 2025;47(4):270–286. (Masterson et al. 2025)
  • DOI:: 10.1159/000545598
  • PMID:: 40188825
  • Study Design:: Retrospective cohort (10 years, Stanford PANS clinic)
  • Key Findings::
    • Proposes standardized terminology: relapsing vs progressive vs monophasic course
    • Largest longitudinal PANS cohort to date
    • Clinical heterogeneity demands mechanism-based subclassification
    • Objective: enable treatment stratification and research consistency
  • Relevance:: 10 years of clinical data show the heterogeneity problem and the need for stratification — the same conclusion reached by ME/CFS researchers. The relapsing-remitting phenotype parallels ME/CFS.
  • Limitations:: Single-center; retrospective; no biomarker correlates.
  • Certainty:: 0.65

28 Meltzer & Van de Water 2017 — Immune System in ASD

  • Full Citation:: Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. Neuropsychopharmacology. 2017;42(1):284–298. (Meltzer and Van de Water 2017)
  • DOI:: 10.1038/npp.2016.158
  • PMID:: 27534269
  • Study Design:: Authoritative review
  • Key Findings::
    • Two axes of immune involvement: prenatal (maternal infection/MIA, maternal anti-brain autoantibodies in ~20% of ASD mothers) and postnatal (inflammation, cytokines, endogenous autoantibodies, T-cell/NK dysfunction)
    • Maternal anti-brain IgG defines a specific ASD subphenotype
    • Animal models: MIA produces ASD-like behavior in offspring
  • Relevance:: Defines the immune-mechanism ASD subgroup that could fit within a broader “neuroimmune encephalopathy spectrum.” The maternal autoantibody subtype (~20%) is a prenatal Architecture B example.
  • Limitations:: Review; causal direction in postnatal immune findings unclear; many associations not replicated.
  • Certainty:: 0.70

29 Braunschweig & Van de Water 2012 — Maternal Autoantibodies in Autism

  • Full Citation:: Braunschweig D, Van de Water J. Maternal autoantibodies in autism. Archives of Neurology. 2012;69(6):693–699. (Braunschweig and Van de Water 2012)
  • DOI:: 10.1001/archneurol.2011.2506
  • PMID:: 22689191
  • Study Design:: Review
  • Key Findings::
    • ~10–23% of mothers of children with ASD have anti-fetal brain protein IgG autoantibodies
    • Gestational immune aberrations (infection, cytokine dysregulation) independently associated with ASD risk
    • Proposal: ASD may contain an immune-mediated subphenotype detectable during pregnancy
  • Relevance:: Establishes prenatal autoantibody-mediated neurodevelopmental phenotype. Different temporality than PANDAS (in utero vs postnatal) but same Architecture B logic: antibody → brain target → psychiatric/neurodevelopmental phenotype.
  • Limitations:: Review; most findings from single research group; replication in independent cohorts ongoing.
  • Certainty:: 0.65

30 Braunschweig et al. 2013 — MAR Autism Antigens

  • Full Citation:: Braunschweig D, Krakowiak P, Duncanson P, et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Translational Psychiatry. 2013;3(7):e277. (Braunschweig et al. 2013)
  • DOI:: 10.1038/tp.2013.50
  • PMID:: 23838888
  • Study Design:: Discovery study (protein array + validation)
  • Key Findings::
    • Identified 7 primary antigens of maternal autoantibody-related (MAR) ASD: LDH-A, LDH-B, cypin, STIP1, CRMP1, CRMP2, YB-1
    • All antigens are highly expressed in developing brain
    • MAR autoantibodies bound fetal but not adult neurons — developmental stage specificity
    • MAR pattern present in ~23% of ASD cases
  • Relevance:: The most specific immune-mechanism ASD biomarker to date. Defines a prenatal autoimmune ASD subgroup analogous to the anti-GPCR autoantibody subgroup in ME/CFS. Demonstrates the principle that autoantibodies can have temporally-specific, development-stage-dependent effects.
  • Limitations:: Single research group; replication ongoing; role of MAR Abs in disease causation vs risk marker unclear.
  • Certainty:: 0.75

31 Croen et al. 2008 — Maternal Anti-Fetal Brain Antibodies

  • Full Citation:: Croen LA, Braunschweig D, Haapanen L, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biological Psychiatry. 2008;64(7):583–588. (Croen et al. 2008)
  • DOI:: 10.1016/j.biopsych.2008.05.006
  • PMID:: 18571628
  • Study Design:: Population-based case-control study (n=84 ASD, 159 DD, 62 GP controls)
  • Key Findings::
    • Maternal mid-pregnancy autoantibodies to fetal brain protein associated with ASD risk
    • 10.5% of ASD mothers had specific anti-fetal brain IgG pattern
    • Specific 37/73 kDa fetal brain protein bands distinguished ASD from controls
  • Relevance:: First population-based evidence for prenatal immune contribution to ASD risk. Establishes that autoantibodies present during gestation — not just at time of diagnosis — are associated with ASD.
  • Limitations:: Modest sample size; retrospective; single geographic region.
  • Certainty:: 0.70

32 Connery et al. 2018 — IVIG in Autoimmune Encephalopathy ASD

  • Full Citation:: Connery K, Tippett M, Delhey LM, et al. Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Translational Psychiatry. 2018;8(1):148. (Connery et al. 2018)
  • DOI:: 10.1038/s41398-018-0214-7
  • PMID:: 30097568
  • Study Design:: Retrospective case series (n=31 treated of 82 screened)
  • Key Findings::
    • Screened 82 children for autoimmune encephalopathy; 49 (60%) recommended IVIG
    • 31 received IVIG under care team supervision
    • 62% of treated showed improvement on CGI scale
    • Subgroup: children with brain autoantibodies (Cunningham Panel positive) showed greater response
  • Relevance:: Links ASD → autoantibody detection → immunotherapy response. Mirrors PANDAS treatment logic. Suggests that autoantibody screening could identify ASD patients responsive to immunomodulation — supporting mechanism-based stratification.
  • Limitations:: Open-label; retrospective; selection bias (only autoimmune-screened patients received IVIG); small sample.
  • Certainty:: 0.55

33 Melamed et al. 2018 — High-Dose IVIG in ASD

  • Full Citation:: Melamed IR, Heffron M, Testori A, Lipe K. A pilot study of high-dose intravenous immunoglobulin 5% for autism: impact on autism spectrum and markers of neuroinflammation. Autism Research. 2018;11(3):421–433. (Melamed et al. 2018)
  • DOI:: 10.1002/aur.1906
  • PMID:: 29427532
  • Study Design:: Pilot study (n=31)
  • Key Findings::
    • ASD children with immune dysregulation treated with high-dose IVIG (2 g/kg)
    • Significant improvement in ABC, SRS, and CARS scores
    • Decreased pro-inflammatory cytokines (IL-2, IL-6, TNF-α)
    • Subset with elevated anti-CAMKII antibodies showed differential response
  • Relevance:: Links CaMKII autoantibodies — the same pathway implicated in PANDAS — to ASD treatment response. First direct biochemical bridge between PANDAS mechanism and ASD subgroup.
  • Limitations:: Pilot; no placebo control; selection bias (immune dysfunction required for enrollment); small sample.
  • Certainty:: 0.50

34 Plioplys 1998 — Negative IVIG Trial in Unselected ASD

  • Full Citation:: Plioplys AV. Intravenous immunoglobulin treatment of children with autism. Journal of Child Neurology. 1998;13(2):79–82. (Plioplys 1998)
  • DOI:: 10.1177/088307389801300207
  • PMID:: 9512308
  • Study Design:: Pilot trial (n=10)
  • Key Findings::
    • 10 autistic children with immunological abnormalities treated with IVIG (400 mg/kg/month x 6 months)
    • No significant improvement in autistic behaviors
    • Only 1/10 showed modest improvement
  • Relevance:: The key negative finding. IVIG does not help unselected ASD — only autoantibody-positive subgroups appear to benefit. Directly supports the stratification imperative: treat the mechanism, not the syndrome.
  • Limitations:: Very small (n=10); low-dose IVIG (400 mg/kg vs modern 1.5–2 g/kg); 1998 diagnostic criteria.
  • Certainty:: 0.60

35 Whiteley et al. 2021 — Autoimmune Encephalitis and ASD

  • Full Citation:: Whiteley P, Marlow B, Kapoor RR, Blagojevic-Stokic N, Sala R. Autoimmune encephalitis and autism spectrum disorder. Frontiers in Psychiatry. 2021;12:775017. (Whiteley et al. 2021)
  • DOI:: 10.3389/fpsyt.2021.775017
  • PMID:: 34975576
  • Study Design:: Narrative review
  • Key Findings::
    • “Acquired autism” hypothesis: AE (anti-NMDAR, etc.) can produce ASD-like phenotype, especially in younger children
    • CSF autoantibodies and inflammatory markers found in AE+ASD patients
    • Reversibility with immunotherapy demonstrates acquired vs innate distinction
    • Maternal valproate, rubella, herpes encephalitis also associated with elevated ASD risk
  • Relevance:: The “acquired autism” concept is a direct parallel to post-infectious ME/CFS. Demonstrates that a condition can be both “autism” (by DSM criteria) and acquired autoimmune encephalitis simultaneously — a contradiction that syndromic labeling cannot resolve.
  • Limitations:: Narrative review; AE presenting as ASD appears rare; causal direction unclear.
  • Certainty:: 0.60

36 Tzang et al. 2019 — Anti-NMDAR Encephalitis Presenting as Autism

  • Full Citation:: Tzang RF, Chang CH, Chang YC, Lane HY. Autism associated with anti-NMDAR encephalitis: glutamate-related therapy. Frontiers in Psychiatry. 2019;10:440. (Tzang et al. 2019)
  • DOI:: 10.3389/fpsyt.2019.00440
  • PMID:: 31293459
  • Study Design:: Case report + review
  • Key Findings::
    • Anti-NMDAR encephalitis can present as ASD in children
    • Proposed pathway: autoantibody → NMDAR hypofunction → glutamate/GABA imbalance → ASD symptoms
    • Treatment: immunotherapy + memantine (NMDA partial agonist) shows symptomatic benefit
    • Demonstrates antibody → specific neurotransmitter dysfunction → neuropsychiatric phenotype pathway
  • Relevance:: A concrete example of Architecture B in autism: a specific antibody → specific receptor → specific neurotransmitter dysfunction → phenotype. Memantine response suggests downstream neural consequences are partially reversible.
  • Limitations:: Case-based; anti-NMDAR encephalitis rare; extrapolation to broader ASD populations uncertain.
  • Certainty:: 0.55

37 Aslan et al. 2021 — Anti-Neuronal Antibodies and Regression in ASD

  • Full Citation:: Aslan C, Konuşkan B, Şener B, Ünal F. Comparison of serum anti-neuronal antibody levels in patients having autism spectrum disorder with and without regression. The Turkish Journal of Pediatrics. 2021;63(5):780–789. (Aslan et al. 2021)
  • DOI:: 10.24953/turkjped.2021.05.006
  • PMID:: 34738360
  • Study Design:: Cross-sectional (n=50)
  • Key Findings::
    • 24 with autistic regression, 26 with classic non-regressive ASD
    • Anti-basal ganglia antibodies and anti-dopamine receptor antibodies measured
    • No significant difference between regressive and non-regressive groups in antibody prevalence
    • ~20% of all ASD had elevated anti-neuronal antibodies — immune subgroup exists regardless of onset type
  • Relevance:: Weakens the argument that regression specifically indicates immune etiology, but strengthens the argument that an immune subgroup exists across ASD. Anti-neuronal antibody prevalence (~20%) roughly matches maternal autoantibody prevalence — suggesting immune mechanisms may characterize a consistent fraction.
  • Limitations:: Very small sample (n=50); single center; antibody assays of uncertain sensitivity.
  • Certainty:: 0.45

References

Aslan, Cihan, Bahadır Konuşkan, Burçin Şener, and Fatih Ünal. 2021. “Comparison of Serum Anti-Neuronal Antibody Levels in Patients Having Autism Spectrum Disorder with and Without Regression.” The Turkish Journal of Pediatrics 63 (5): 780–89. https://doi.org/10.24953/turkjped.2021.05.006.
Bateman, Lucinda, Alison C. Bested, Hector F. Bonilla, Bela V. Chheda, Lily Chu, Jennifer M. Curtin, Tania T. Dempsey, et al. 2021. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.” Mayo Clinic Proceedings 96 (11): 2861–78. https://doi.org/10.1016/j.mayocp.2021.07.004.
Bontempo, Alyssa C., Jennifer M. Bontempo, and Paul R. Duberstein. 2025. “Ignored, Dismissed, and Minimized: Understanding the Harmful Consequences of Invalidation in Health Care—a Systematic Meta-Synthesis of Qualitative Research.” Psychological Bulletin 151 (4): 399–427. https://doi.org/10.1037/bul0000473.
Braunschweig, Daniel, Paula Krakowiak, Paul Duncanson, Ryan Boyce, Robin L Hansen, Paul Ashwood, Irva Hertz-Picciotto, Isaac N Pessah, and Judy Van de Water. 2013. “Autism-Specific Maternal Autoantibodies Recognize Critical Proteins in Developing Brain.” Translational Psychiatry 3 (7): e277. https://doi.org/10.1038/tp.2013.50.
Braunschweig, Daniel, and Judy Van de Water. 2012. “Maternal Autoantibodies in Autism.” Archives of Neurology 69 (6): 693–99. https://doi.org/10.1001/archneurol.2011.2506.
Cesaroni, Carlo Alberto, Giulia Pisanò, Susanna Rizzi, Agnese Pantani, Daniele Frattini, and Carlo Fusco. 2026. “PANDAS Syndrome: A Narrative Review of the Diagnostic Conundrum in Children with Acute Neuropsychiatric Symptoms.” International Journal of Molecular Sciences 27 (10): 4612. https://doi.org/10.3390/ijms27104612.
Chang, Kiki, Jennifer Frankovich, Michael Cooperstock, Madeleine W Cunningham, M Elizabeth Latimer, Tanya K Murphy, Mark Pasternack, et al. 2015. “Clinical Evaluation of Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference.” Journal of Child and Adolescent Psychopharmacology 25 (1): 3–13. https://doi.org/10.1089/cap.2014.0084.
Chiarello, Francesca, Silvia Spitoni, Eric Hollander, Marco Matucci Cerinic, and Stefano Pallanti. 2017. “An Expert Opinion on PANDAS/PANS: Highlights and Controversies.” International Journal of Psychiatry in Clinical Practice 21 (2): 91–98. https://doi.org/10.1080/13651501.2017.1285941.
Connery, Kathleen, Marie Tippett, Leanna M Delhey, Shannon Rose, John C Slattery, Stephen G Kahler, Juergen Hahn, et al. 2018. “Intravenous Immunoglobulin for the Treatment of Autoimmune Encephalopathy in Children with Autism.” Translational Psychiatry 8 (1): 148. https://doi.org/10.1038/s41398-018-0214-7.
Croen, Lisa A, Daniel Braunschweig, Lori Haapanen, Cathleen K Yoshida, Bruce Fireman, Judith K Grether, Martin Kharrazi, Robin L Hansen, Paul Ashwood, and Judy Van de Water. 2008. “Maternal Mid-Pregnancy Autoantibodies to Fetal Brain Protein: The Early Markers for Autism Study.” Biological Psychiatry 64 (7): 583–88. https://doi.org/10.1016/j.biopsych.2008.05.006.
Endres, Dominique, Thomas A Pollak, Karl Bechter, Dominik Denzel, Karoline Pitsch, Kathrin Nickel, Kimon Runge, et al. 2022. “Immunological Causes of Obsessive-Compulsive Disorder: Is It Time for the Concept of an “Autoimmune OCD” Subtype?” Translational Psychiatry 12 (1): 5. https://doi.org/10.1038/s41398-021-01700-4.
Frankovich, Jennifer, Susan Swedo, Tanya Murphy, Russell C Dale, Dritan Agalliu, Kyle Williams, Michael Daines, et al. 2017. “Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II—Use of Immunomodulatory Therapies.” Journal of Child and Adolescent Psychopharmacology 27 (7): 574–93. https://doi.org/10.1089/cap.2016.0148.
Frankovich, Jennifer, Margo Thienemann, Jennifer Pearlstein, Amber Crable, Kayla Brown, and Kiki Chang. 2015. “Multidisciplinary Clinic Dedicated to Treating Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome: Presenting Characteristics of the First 47 Consecutive Patients.” Journal of Child and Adolescent Psychopharmacology 25 (1): 38–47. https://doi.org/10.1089/cap.2014.0081.
Kingdon, Caroline C, Erinna W Bowman, Hayley Curran, Luis Nacul, and Eliana M Lacerda. 2018. “Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls.” PharmacoEconomics - Open 2 (4): 381–92. https://doi.org/10.1007/s41669-018-0071-6.
Kirvan, Christine A, Susan E Swedo, Janet S Heuser, and Madeleine W Cunningham. 2003. “Mimicry and Autoantibody-Mediated Neuronal Cell Signaling in Sydenham Chorea.” Nature Medicine 9 (7): 914–20. https://doi.org/10.1038/nm892.
Kirvan, Christine A, Susan E Swedo, David Kurahara, and Madeleine W Cunningham. 2006. “Streptococcal Mimicry and Antibody-Mediated Cell Signaling in the Pathogenesis of Sydenham’s Chorea.” Autoimmunity 39 (1): 21–29. https://doi.org/10.1080/08916930500484757.
Kovacevic, Miro, Paul Grant, and Susan E Swedo. 2015. “Use of Intravenous Immunoglobulin in the Treatment of Twelve Youths with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.” Journal of Child and Adolescent Psychopharmacology 25 (1): 65–69. https://doi.org/10.1089/cap.2014.0067.
La Bella, Saverio, Giovanna Scorrano, Marta Rinaldi, Armando Di Ludovico, Francesca Mainieri, Marina Attanasi, Alberto Spalice, Francesco Chiarelli, and Luciana Breda. 2023. “Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS): Myth or Reality? The State of the Art on a Controversial Disease.” Microorganisms 11 (10): 2549. https://doi.org/10.3390/microorganisms11102549.
Latimer, M Elizabeth, Nathan L’Etoile, Jakob Seidlitz, and Susan E Swedo. 2015. “Therapeutic Plasma Apheresis as a Treatment for 35 Severely Ill Children and Adolescents with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.” Journal of Child and Adolescent Psychopharmacology 25 (1): 70–75. https://doi.org/10.1089/cap.2014.0080.
Masterson, Erin E, Kate Miles, Noelle Schlenk, Cindy Manko, Meiqian Ma, Bahare Farhadian, Kiki Chang, Melissa Silverman, Margo Thienemann, and Jennifer Frankovich. 2025. “Defining Clinical Course of Patients Evaluated for Pediatric Acute-Onset Neuropsychiatric Syndrome: Phenotypic Classification Based on 10 Years of Clinical Data.” Developmental Neuroscience 47 (4): 270–86. https://doi.org/10.1159/000545598.
Melamed, Isaac R, Melinda Heffron, Alessandro Testori, and Kellie Lipe. 2018. “A Pilot Study of High-Dose Intravenous Immunoglobulin 5
for Autism: Impact on Autism Spectrum and Markers of Neuroinflammation.” Autism Research 11 (3): 421–33. https://doi.org/10.1002/aur.1906.
Meltzer, Amory, and Judy Van de Water. 2017. “The Role of the Immune System in Autism Spectrum Disorder.” Neuropsychopharmacology 42 (1): 284–98. https://doi.org/10.1038/npp.2016.158.
Muirhead, Nina, John Muirhead, Gareth Lavery, and Ben Marsh. 2021. “Medical School Education on Myalgic Encephalomyelitis.” Medicina 57 (6): 542. https://doi.org/10.3390/medicina57060542.
Murphy, Tanya K, Diana M Gerardi, and James F Leckman. 2014. “Pediatric Acute-Onset Neuropsychiatric Syndrome.” The Psychiatric Clinics of North America 37 (3): 353–74. https://doi.org/10.1016/j.psc.2014.06.001.
Parslow, Roxanne M., Alison Shaw, Kirstie L. Haywood, and Esther Crawley. 2017. “Important Factors to Consider When Treating Children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Perspectives of Health Professionals from Specialist Services.” BMC Pediatrics 17 (1): 43. https://doi.org/10.1186/s12887-017-0799-7.
Plioplys, A V. 1998. “Intravenous Immunoglobulin Treatment of Children with Autism.” Journal of Child Neurology 13 (2): 79–82. https://doi.org/10.1177/088307389801300207.
Podell, Richard, Mary E. Dimmock, and Barbara B. Comerford. 2020. “Documenting Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Work 66 (2): 339–52. https://doi.org/10.3233/WOR-203178.
Sigra, Sofia, Eva Hesselmark, and Susanne Bejerot. 2018. “Treatment of PANDAS and PANS: A Systematic Review.” Neuroscience & Biobehavioral Reviews 86: 51–65. https://doi.org/10.1016/j.neubiorev.2018.01.001.
Smith, M. E. Beth, Heidi D. Nelson, Elizabeth Haney, Miranda Pappas, Monica Daeges, Ngoc Wasson, and Marian McDonagh. 2014. “Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Evidence Report/Technology Assessment, no. 219: 1–433. https://doi.org/10.23970/AHRQEPCERTA219.
Swedo, Susan E, Henrietta L Leonard, Marjorie Garvey, Barbara Mittleman, Albert J Allen, Susan Perlmutter, Lorraine Lougee, Sara Dow, Jason Zamkoff, and Billie K Dubbert. 1998. “Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections: Clinical Description of the First 50 Cases.” The American Journal of Psychiatry 155 (2): 264–71. https://doi.org/10.1176/ajp.155.2.264.
Thornton, Emily J., Lawrence D. Hayes, Daniel S. Goodwin, Nicholas Sculthorpe, Yeliz Prior, and Nilihan E. M. Sanal-Hayes. 2025. “Managing Energy, and Shaping Care: Insights from Adults with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through Co-Production Workshops.” American Journal of Medicine 138 (6): 1001–9. https://doi.org/10.1016/j.amjmed.2025.02.008.
Tzang, Ruu-Fen, Chuan-Hsin Chang, Yue-Cune Chang, and Hsien-Yuan Lane. 2019. “Autism Associated with Anti-NMDAR Encephalitis: Glutamate-Related Therapy.” Frontiers in Psychiatry 10: 440. https://doi.org/10.3389/fpsyt.2019.00440.
Vreeland, Allison, Denise Calaprice, Noga Or-Geva, Richard E Frye, Dritan Agalliu, Herbert M Lachman, Christopher Pittenger, et al. 2023. “Postinfectious Inflammation, Autoimmunity, and Obsessive-Compulsive Disorder: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection, and Pediatric Acute-Onset Neuropsychiatric Disorder.” Developmental Neuroscience 45 (6): 361–74. https://doi.org/10.1159/000534261.
Whiteley, Paul, Ben Marlow, Ritika R Kapoor, Natasa Blagojevic-Stokic, and Regina Sala. 2021. “Autoimmune Encephalitis and Autism Spectrum Disorder.” Frontiers in Psychiatry 12: 775017. https://doi.org/10.3389/fpsyt.2021.775017.
Williams, Kyle A, Susan E Swedo, Cristan A Farmer, Heidi Grantz, Paul J Grant, Precilla D’Souza, Rebecca Hommer, Liliya Katsovich, Robert A King, and James F Leckman. 2016. “Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.” Journal of the American Academy of Child and Adolescent Psychiatry 55 (10): 860–867.e2. https://doi.org/10.1016/j.jaac.2016.06.017.